Inventor
R. Blake Pepinsky
Inventor
Arlington, MA, US
Overview
Patents· 50 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides27%
A61KPreparations for medical, dental or toiletry purposes26%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%
C12NMicroorganisms or enzymes13%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C12YEnzymes3%
A01KAnimal husbandry2%
Y02ATechnologies for adaptation to climate change2%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds1%
C08LCompositions of macromolecular compounds1%
PatentTitleYear
10,308,706Methods of preventing and removing trisulfide bonds20199,796,780'LINGO-2 antagonists for treatment of conditions involving motor neurons'20179,745,375'Compositions comprising antibodies to LINGO or fragments thereof'20179,228,015'Nogo receptor antagonists and methods of increasing neurite outgrowth'20169,066,984'Sp35 antibodies and uses thereof'20159,068,992'Screening methods for identifying Sp35 antagonists'20159,005,926'Methods of preventing and removing trisulfide bonds'20158,969,042'Refolding transforming growth factor beta family proteins'20158,932,821'NOGO receptor binding protein'20158,894,999'Use of DR6 and p75 antagonists to promote survival of cells of the nervous system'20148,765,662'NOGO receptor binding protein'20148,722,862'Refolding transforming growth factor beta family proteins'20148,669,345'Nogo receptor antagonists'20148,642,732'Polymer-conjugated glycosylated neublastin'20148,609,407'Sp35 antibodies and uses thereof'20138,551,476'SP35 antibodies and uses thereof'20138,524,660'Polyalkylene polymer compounds and uses thereof'20138,501,178'Use of DR6 and p75 antagonists to promote survival of cells of the nervous system'20138,486,893'Treatment of conditions involving demyelination'20138,425,910'Composition comprising antibodies to LINGO or fragments thereof'20138,410,061'Functional antagonists of hedgehog activity'20138,263,553'Neublastin variants'20128,163,875'Polymer conjugated glycosylated neublastin'20128,153,580'Nogo receptor binding protein'20128,128,926'Sp35 antibodies and uses thereof'20128,119,114'Polymer conjugates of mutated neublastin'20128,058,406'Composition comprising antibodies to LINGO or fragments thereof'20118,030,456'Nogo receptor antagonists'20118,017,733'Polyalkylene polymer compounds and uses thereof'20117,785,829'Nogo receptor binding protein'20107,465,705'Nogo receptor antagonists'20087,442,370'Polymer conjugates of mutated neublastin'20087,196,112'Cell adhesion inhibitors'20076,897,297'Hydrophobically-modified protein compositions and methods'20056,444,793'Hydrophobically-modified hedgehog protein compositions and methods'20026,316,003'Tat-derived transport polypeptides'20016,127,332'Muteins of IFN-.beta.'20005,804,604'Tat-derived transport polypeptides and fusion proteins'19985,747,641'Tat-derived transport polypeptide conjugates'19985,674,980'Fusion protein comprising tat-derived transport moiety'19975,670,617'Nucleic acid conjugates of tat-derived transport polypeptides'19975,652,122'Nucleic acids encoding and methods of making tat-derived transport polypeptides'19975,545,723'Muteins of IFN-.beta.'19965,484,711'DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI'19965,359,033'Cleaved dimers of mullerian inhibiting substance-like polypeptides'19945,298,489'DNA sequences recombinant DNA molecules and processes for producing lipocortins III, IV, V and VI'19945,081,019'DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides'19924,950,646'DNA sequences, recombinant DNA molecules and processes for producing human lipocortin-like polypeptides'19904,879,224'DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides'19894,874,743'DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor-like polypeptides'1989Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1989–2002Patents assigned to BIOGEN INC (15)· patent assignee history
1989–2000Based in Watertown, MA, US· patent location history
1997–2019Based in Arlington, MA, US· patent location history
2005–2016Patents assigned to BIOGEN IDEC INC (30)· patent assignee history
2011–2015Patents assigned to PEPINSKY R BLAKE (18)· patent assignee history
2011–2014Patents assigned to MI SHA (9)· patent assignee history
2015–2019Patents assigned to BIOGEN MA INC (5)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BIOGEN IDEC INC | 30 | 2005–2016 |
| PEPINSKY R BLAKEself | 18 | 2011–2015 |
| BIOGEN INC | 15 | 1989–2002 |
| MI SHA | 9 | 2011–2014 |
| BIOGEN MA INC | 5 | 2015–2019 |
Locations
| Location | Patents | Span |
|---|---|---|
| Arlington, Massachusetts, US | 41 | 1997–2019 |
| Watertown, Massachusetts, US | 9 | 1989–2000 |